Who are Palbociclib + Letrozole OR Fulvestrant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/palbociclib-letrozole-or-fulvestrant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Palbociclib + Letrozole OR Fulvestrant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Palbociclib + Letrozole OR Fulvestrant (Palbociclib + Letrozole OR Fulvestrant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor + endocrine therapy (aromatase inhibitor or selective estrogen receptor degrader). Area: Oncology.

phase 3 CDK4/6 inhibitor + endocrine therapy (aromatase inhibitor or selective estrogen receptor degrader) CDK4/6 (palbociclib); Aromatase (letrozole) or Estrogen Receptor (fulvestrant) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Palbociclib + Letrozole OR Fulvestrant (Palbociclib + Letrozole OR Fulvestrant) — SOLTI Breast Cancer Research Group. Palbociclib inhibits cyclin-dependent kinases 4 and 6 to block cell cycle progression, combined with either letrozole (aromatase inhibitor) or fulvestrant (estrogen receptor antagonist) to suppress hormone-driven breast cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Palbociclib + Letrozole OR Fulvestrant TARGET	Palbociclib + Letrozole OR Fulvestrant	SOLTI Breast Cancer Research Group	phase 3	CDK4/6 inhibitor + endocrine therapy (aromatase inhibitor or selective estrogen receptor degrader)	CDK4/6 (palbociclib); Aromatase (letrozole) or Estrogen Receptor (fulvestrant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor + endocrine therapy (aromatase inhibitor or selective estrogen receptor degrader) class)

SOLTI Breast Cancer Research Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palbociclib + Letrozole OR Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/palbociclib-letrozole-or-fulvestrant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab